ADAPT® treated tissue has been scientifically proven to more closely mimic the characteristics of normal human tissue which promotes a more tolerant immune response and improved tissue ingrowth. Our clinically superior ADAPT® products are the only ones to have achieved over ten years without calcification or degradation. With the potential for a product lifespan free from calcification, physicians can potentially intervene across a broader age spectrum and provide their patients with a solution for life. All Admedus ADAPT® products are manufactured in our state-of-the-art biomanufacturing facility which has substantial capacity to expand and includes an in-house research and development laboratory.

EVIDENCE of LONG-TERM DURABILITY1

  • ▶︎ 25 patients were followed for up to 10 years
  • ▶︎ No graft failure, thromboembolic events, infections or device-related reinterventions
  • ▶︎ Echocardiographic assessment demonstrated the absence of calcification in all implants
LARGEST PATIENT SERIES EVER IN CARDIAC SURGERY2
  • ▶︎ Largest patient series in congenital heart surgery
  • ▶︎ Multi-center study (3 centers, 501 implants, 377 patients)
  • ▶︎ Wide range of application show excellent durability for CHD repair
  • ▶︎ No evidence of calcification (echocardiographic or radiologic)
  • ▶︎ ADAPT® bioscaffold performs comparably in the systematic and pulmonary circulations in neonates, infants and older children
PROVEN REMODELING and TRANSFORMATIVE HEALING3

  • ▶︎ Stable ADAPT® bioscaffold without inflammatory response or calcification
  • ▶︎ Successful fibroblastic infiltration and new collagen throughout bioscaffold
  • ▶︎ Neovascularization is also demonstrated

References:
[1] Neethling, et al. Performance of the ADAPT® treated BioScaffold in paediatric patients with congenital cardiac anomalies: Medium to Long-Term Outcomes. Presented at the Joint European Congenital Heart Surgeons Society and World Society for Pediatric and Congenital Heart Surgery Congress. 20-22 June 2019. Sofia, Bulgaria.
[2] Bell D, Betts K, Justo R, Forde N, Venugopal P, Corno AF, Smith P, Caputo M, Marsico R, Karl TR, Alphonso N. Multi-centre experience with 500 CardioCel® implants used for the repair of congenital heart defects, The Annals of Thoracic Surgery (2019), doi: https://doi.org/10.1016/j.athoracsur.2019.04.085.
[3] Prabu S, Armes JE, Bell D, Justo R, Venuqopal P, Karl T, Alphonso N. Histologic Evaluation of Explanted Tissue-Engineered Bovine Pericardium (CardioCel). Semin Thorac Cardiovasc Surg. 2017 Autumn;29(3):356-363